MONARI

Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases; Pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of the aforesaid diseases